GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » Current Ratio

Everest Medicines (HKSE:01952) Current Ratio : 8.36 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Everest Medicines's current ratio for the quarter that ended in Dec. 2023 was 8.36.

Everest Medicines has a current ratio of 8.36. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Everest Medicines's Current Ratio or its related term are showing as below:

HKSE:01952' s Current Ratio Range Over the Past 10 Years
Min: 0.26   Med: 6.14   Max: 24.06
Current: 8.36

During the past 6 years, Everest Medicines's highest Current Ratio was 24.06. The lowest was 0.26. And the median was 6.14.

HKSE:01952's Current Ratio is ranked better than
76.74% of 1552 companies
in the Biotechnology industry
Industry Median: 3.78 vs HKSE:01952: 8.36

Everest Medicines Current Ratio Historical Data

The historical data trend for Everest Medicines's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines Current Ratio Chart

Everest Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial 0.26 24.06 9.95 3.92 8.36

Everest Medicines Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.95 2.37 3.92 15.85 8.36

Competitive Comparison of Everest Medicines's Current Ratio

For the Biotechnology subindustry, Everest Medicines's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Everest Medicines's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Everest Medicines's Current Ratio distribution charts can be found below:

* The bar in red indicates where Everest Medicines's Current Ratio falls into.



Everest Medicines Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Everest Medicines's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=2742.774/328.273
=8.36

Everest Medicines's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=2742.774/328.273
=8.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Everest Medicines  (HKSE:01952) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Everest Medicines Current Ratio Related Terms

Thank you for viewing the detailed overview of Everest Medicines's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Everest Medicines (HKSE:01952) Business Description

Traded in Other Exchanges
Address
1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.

Everest Medicines (HKSE:01952) Headlines

No Headlines